EAU 2021: Treatment Challenges to BCG Unresponsive Non-Muscle Invasive Bladder Cancer

Dr. Keisuke Shigeta from Tokyo, Japan joined the Joint Session of the European Association of Urology and Japanese Urological Association at the 2021 EAU annual meeting to discuss treatment challenges in BCG unresponsive non-muscle invasive bladder cancer (NMIBC). Dr. Shigeta notes that there are important definitions for the BCG treatment of NMIBC, highlighted as follows: […]

EAU 2021: Is Nuclear Medicine Taking over the Treatment of Metastatic Prostate Cancer? PRLT Is Only a Tessera in the Treatment of CRPC

(UroToday.com) The European Association of Urology (EAU) 2021 Virtual Annual Meeting included a joint session of the EAU and the Canadian Urological Association and a presentation by Dr. Frederic Pouliot suggesting that prostate radioligand therapy is only a tessera in the treatment of CRPC. Dr. Pouliot notes that theranostics is the combination of imaging and therapy, […]

EAU 2021: Is Nuclear Medicine Taking over the Treatment of Metastatic Prostate Cancer? PRLT Could Do Much More If Applied Earlier and Repetitive

(UroToday.com) The European Association of Urology (EAU) 2021 Virtual Annual Meeting included a joint session of the EAU and the Canadian Urological Association and a presentation by Dr. Christian La Fougere discussing prostate radioligand therapy and its use earlier in the disease process. Dr. La Fougere notes that the theranostic key-lock principle includes a target (ie. […]

EAU 2021: Can Prostate Cancer Follow-up Databases Safely Reduce Clinic Numbers

(UroToday.com) At the 2021 European Association of Urology (EAU) virtual annual meeting, Dr. Stephen Mark discussed aspects of a prostate cancer follow-up database to safely reduce patient clinic visits. Dr. Mark notes that there is generally a wide variation in prostate cancer follow-up, with options for follow-up including in-person clinic visits, telehealth, general practitioner (60% compliance) […]

X